Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Local administration of antibodies in inflammatory bowel diseases using non-crosslinked gelatin nanoparticles

Marc Schneider – Head of the Institute, Biopharmaceutics and Pharmaceutical Technology, Saarland University
Introduction:

Since the number of approved biologics in the EU is steadily increasing, reaching an all-time high in 2025, there is a huge interest in improving the formulation of those hydrophilic macromolecules 1. Due to limited stability and tissue penetration, nowadays they are mainly administered by injection.

Infliximab (IFX), a common therapy option for inflammatory bowel diseases (IBD), suffers from a loss of response over time2. To address this, a coated crosslinker-free gelatin nanoparticle (cGNP) system is developed to enable oral or rectal application, aiming to reduce dose, systemic side effects and enhance compliance.

Learning Objectives:

  • understand the advantages of gelatin nanoparticles as a carrier for hydrophilic macromolecules.
  • see the effects of different parameters during manufacturing of coated gelatin nanoparticles on the particle size.